Previous 10 | Next 10 |
home / stock / pddpf / pddpf news
MONTREAL, Aug. 21, 2020 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP, OTCQX: MEDXF; PDDPF) today announces that it has begun trading on the OTCQX ® Best Market under the new ticker “MEDXF,” e...
Medexus Pharmaceuticals ( OTCQX:PDDPF ) : Q1 Net loss of C$4.8M vs. C$2.2M in year ago quarter. More news on: Medexus Pharmaceuticals Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Strong organic growth across all key product lines, including recently acquired IXINITY ® Generated $4.1 million of cash flow from operations Management to host conference call at 8:00 AM ET on Wednesday, August 12, 2020 TORONTO, CHICAGO and MONTREAL, Aug. 11, 2020 (GLOBE...
MONTREAL, Aug. 11, 2020 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP, OTCQX: PDDPF) today announced that it will be presenting at the Canaccord Genuity 40 th Annual Growth Conference being held virtually on August 11...
MONTREAL, Aug. 05, 2020 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP, OTCQX: PDDPF) today announced that it plans to host a conference call at 8:00 AM Eastern Time on Wednesday, August 12, 2020 to discuss the Company&...
NEW YORK , Aug. 4, 2020 /PRNewswire/ -- OTC Markets Group Inc. (OTCQX: OTCM), operator of financial markets for 10,000 U.S. and global securities, today announced Medexus Pharmaceuticals Inc. (TSX-V: MDP; OTCQX: PDDPF), a commercial-stage specialty pharmaceutical c...
Medexus Pharmaceuticals ( OTCQB:PDDPF ) announced that Triamcinolone Hexacetonide Injectable Suspension 20 mg/mL (TH) has been approved for inclusion on the Alberta Drug Benefit List (ADBL), the Saskatchewan Drug Plan, Newfoundland and Labrador Prescription Drug Program (NLPDP) a...
MONTREAL, July 09, 2020 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP, OTCQB: PDDPF) is pleased to announce that Triamcinolone Hexacetonide Injectable Suspension 20 mg/mL (TH) has been approved for inclusion on t...
Transformative acquisition of IXINITY® completed February 28, 2020 Fiscal 2020 Metoject® unit market demand increased 96%; Rupall™ unit market demand increased 61%; and Rasuvo® unit market demand increased 11% Medexus management to host conference call a...
MONTREAL, June 17, 2020 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus”) (TSXV: MDP, OTCQB: PDDPF) today announced that it plans to host a conference call at 8:00 AM Eastern Time on Tuesday, June 23, 2020 to discuss the Company ...
News, Short Squeeze, Breakout and More Instantly...
Medexus Pharmaceuticals Inc Company Name:
PDDPF Stock Symbol:
OTCMKTS Market:
TORONTO and CHICAGO and MONTREAL, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “ Company ” or “ Medexus ”) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) announced its financial and operating results for the three and six mon...
TORONTO, CHICAGO and MONTREAL, Nov. 16, 2020 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “Medexus” ) ( TSXV: MDP , OTCQ X : MEDXF ) today announced it has reached the 50% e...
MONTREAL, Nov. 09, 2020 (GLOBE NEWSWIRE) -- Medexus Pharmaceuticals Inc. (the “Company” or “ Medexus ) (TSXV: MDP) (OTCQX: MEDXF) (Frankfurt: P731) today announced that it plans to host a conference call at 8:00 AM Eastern Time on Tuesday, November 1...